RIGL Q4 2017 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$12M

Operating Income

-$26M

Net Income

-$26M

EPS (Diluted)

$-1.79

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$119M

Total Liabilities

$18M

Stockholders' Equity

$101M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	-$12M	-$9M	-33.9%
Operating Income	-$26M	-$16M	-66.1%
Net Income	-$26M	-$16M	-65.9%